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We aimed to estimate the impact of ingestion of a pure protein load on the glucose levels in T1DM patients treated with insulin
pumps. We examined 10 T1DM patients (6 females, mean age—32.3 years, mean HbA1c—6.8%) treated with insulin pumps
equipped with a continuous glucose monitoring system (CGMS). In Phase I, baseline insulin infusion was optimized to minimize
the differences in fasting glucose levels to less than 30mg/dL between any two time points between 9 a.m. and 3 p.m. In Phase
II, the patients were exposed to single pure protein load. CGMS record was performed and the glucose pattern was defined for 6
hours of each phase. The maximal glucose level increment was similar for the entire duration of the fasting and the protein load
test (26.6 versus 27.6mg/dL, resp., 𝑃 < 0.78). There was only a borderline difference in change between baseline versus 6th hour
glucose (12.5 and 19.0mg/dL, 𝑃 = 0.04). Glucose variability, assessed by standard deviation of mean glucose levels, was 36.4 and
37.9mg/dL, respectively (𝑃 = 0.01). The administration of a pure protein load does not seem to have a clinically significant impact
on glucose levels in T1DM patients treated with insulin pumps.
1. Introduction
Nutrition therapy is essential for the management of dia-
betes [1]. It is well recognized that the mealtime insulin
requirement in type 1 diabetes (T1DM) patients is driven
mostly by carbohydrate content and that monitoring it can
improve glucose levels. The American Diabetes Association
recommends meal plans based on carbohydrate counting as
a key strategy to achieve glycemic control [2]. An impact of
protein containing food on glycemia in diabetes has been
studied for many decades; however, it is unclear whether
or not the calculation of other food components can also
be used to optimize glucose levels [3, 4]. Some studies
have suggested that counting the amount of fat and protein
(using fat/protein exchanges) may be beneficial for reaching
glycemic control in T1DM children [5]. Such an approach
could be particularly feasible in T1DM patients treated with
continuous subcutaneous insulin infusion (CSII) via insulin
pump [3]. One of the features implemented in some personal
insulin pumps is the dual-wave bolus (DWB) option, which
delivers the combination of an instant standard premeal
insulin bolus followed by a square bolus (SB) infused over
several hours, helping to tailor prandial insulin delivery to
the composition of a meal [6]. This pump option may be
particularly useful for mixed, fat-/protein-rich meals since
such food seems to modify postmeal glucose patterns with
a less rapid and more prolonged increase in plasma glucose
concentration [7]. It has recently been shown among a
cohort of pediatric patients with long-lasting T1DM, using
pump therapy, that for mixed meals insulin dosing based on
both carbohydrate and fat/protein counting leads to lower
postprandial glycemic levels than the conventional counting
of carbohydrates only. [8]. However, the studies performed
so far estimating the glycemic effect, mostly on postprandial
glucose levels, of fat and protein ingestion had some serious
limitations. For example, they evaluated either the effect of
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a meal containing both fat and protein [5, 8] or the effect
of just fat added to a mixed meal [9]. To our knowledge,
until now no study has examined the effect of sole protein
ingestion.
The aim of this study was to estimate the impact of
ingestion of a pure protein load on glucose levels in T1DM
patients treated with personal insulin pumps.
2. Methods
We examined 10 T1DM patients (6 females, 4 males) treated
with insulin pumps (Medtronic Paradigm 722 or Veo)
equipped with a continuous glucose monitoring system
(CGMS) option.During the study, Enlite sensors (Medtronic)
were used exclusively. All of the patients were white Cau-
casians under the medical care of the Department of
MetabolicDiseases,UniversityHospital, Krakow, Poland.The
selection of patients was based on good prestudy compliance
as assessed by good glycemic control (HbA1c level less than
7.5%, 58mmol/mol), the patient’s usage of the Bolus Wizard
(bolus calculator) option for more than 90% of boluses,
changing infusion sets according to manufacturer’s recom-
mendation, and using at least one electrode for CGMS per
month during the preceding year.The study participants were
free from advanced chronic complications of diabetes. All
patients gave informed consent, and the study was approved
by the Bioethical Committee of the Jagiellonian University.
Before study entry (one to two weeks preceding Day
1), the patients’ baseline insulin infusion was optimized to
minimize the differences in fasting glucose levels to less
than 30mg/dL between any two time points between 9
a.m. and 3 p.m. The procedure of optimization was based
on a retrospective analysis of CGMS records and involved
increasing or decreasing the rate of basal insulin infusion
two hours before the observed rise or fall in glucose level.
Subsequently, the new settings of the basal infusion rate were
rechecked with CGMS to meet the study criteria. In Phase
I (Day 1), a fasting test (between 9 a.m. and 3 p.m.) was
performed to confirm the stable glucose patterns (as defined
above) on current basal insulin infusion settings.
In Phase II (Day 2), the patients were exposed to a
single pure protein load by ingesting a commercially available
preparation (Protifar, Nutricia, milk derived proteins). In its
100mL volume, the product contained 88.5 grams of pure
protein, 1.6 grams of fat, and less than 1.5 grams of carbo-
hydrates (lactose), as well as minerals and micronutrients.
All the patients were exposed to a dose of 0.3 g of pure
protein (0.34mL of Protifar/kg dissolved in 200mL of water)
for each kg of body weight; the load was administered at 9
a.m. Such a dose of protein is the equivalent of the usual
protein portion in a medium-size meal, based on the dietary
recommendations for patients with diabetes (15–20% of total
daily energy intake) [2]. Both phases were performed in
home settings; the patients were given precise instructions
concerning the procedure.
The rate of basal insulin infusion during the protein
load test was the same as that defined initially in Phase I;
no modifications or extra insulin boluses were permitted.
Table 1: Clinical characteristics of study participants.
Variable Whole study group
Mean SD Median
Gender F/M [𝑛/𝑛] 6/4 — —
HbA1c [% | mmol/mol] 6.8 | 51 0.4 | 4 6.9 | 52
Age at time of examination
[yrs] 32.3 8.6 30.5
T1DM duration [yrs] 11.7 6.4 9.5
Weight [kg] 71.1 12.7 70.6
Average daily insulin dose
per kg of body mass [IU/kg] 0.53 0.06 0.54
Average percentage of basal
insulin [%] 40.9 3.4 40.5
CGMS record was performed in both phases, during which
the patients avoided physical activity. Glucose patterns were
recorded during 6 hours of Phase I (fasting) and 6 hours of
Phase II (protein load).
There was no consistency in the age of CGM sensors
during Phase I and Phase II; however, we strictly avoided
performing tests during the first or last (6th) day after sensor
insertion.
The statistical analysis was performed using STATISTICA
10.0 software. The difference between the two phases was
assessed by using the dependent t-test or paired sample
Wilcoxon signed rank test, when applicable.
3. Results
The patients’ mean age was 32.3 years, mean T1DM duration
was 11.7 years, and mean HbA1c was 6.85% (51mmol/mol).
The clinical characteristics of the study participants are pre-
sented in Table 1. Mean baseline glucose levels were 119.8 and
117.6mg/dL for Phase I and Phase II, respectively (𝑃 = 0.68).
Mean maximal glucose levels were 146.4 and 145.2mg/dL for
Phase I and Phase II, respectively (𝑃 = 0.85). Mean maximal
glucose level increment was similar for the entire 6-hour
fasting and protein load test (26.6mg/dL versus 27.6mg/dL,
resp., 𝑃 = 0.78) (Figure 1). There was only a borderline
difference between the change in baseline versus 6th hour
glucose levels for the fasting state versus protein load test
(12.5mg/dL and 19.0mg/dL, resp., 𝑃 = 0.04). The glucose
variability assessed by CGMS-based standard deviation of
mean glucose levels was 36.4 and 38.9mg/dL for Phase I and
Phase II, respectively (𝑃 = 0.01).
There were no episodes of infusion set malfunctions
during Phase I or Phase II of the study, and no hypoglycemia
was recorded during fasting or after loading.
4. Discussion
Here, for the first time, we evaluated the impact of the
ingestion of a pure protein load on glucose levels in adult
T1DM subjects treatedwith insulin pumps. In this short-term
clinical experiment, we found that protein consumption had
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Figure 1: Glucose patterns in the study subjects during fasting state
and after protein load, for the same rate of basal insulin dose. Data
are presented as mean glucose and standard deviation.
very little effect on the glycemia of the examined cohort of
patients.
Contradictory to our study results, there have been
several earlier papers reporting a substantial rise in glucose
levels in T1DM patients as an effect of the consumption
of noncarbohydrate food components [5, 8, 10]. However,
these reports involved either fat only or fat and protein
combined, because, in real-life settings, they are often con-
sumed together in products chosen by diabetic individuals,
such as meat, poultry, fish, and dairy products. Thus, the
discrepancy between earlier studies and our results may be
explained by the variable short-term impact of fat and protein
versus protein only consumption on glucose homeostasis
through different mechanisms of hepatic gluconeogenesis,
postmeal insulin resistance, release of glucagon and gut
hormones, gastric emptying, and rate of absorption of other
food components like carbohydrates and other factors [11–
13]. There are some earlier reports from different healthy and
diabetic populations suggesting variable glycemic effects of
high protein meals; for example, they promote gluconeogen-
esis and slow gastric emptying [13, 14]. In a recently published
study in T1DM, it was shown that a mixed meal consisting of
30 g of carbohydrate and 40 g of protein has a greater glycemic
effect than a pure carbohydrate load [10]. This seems to be in
conflict with the results of our analysis. However, there were
substantial differences between the two studies. The study by
Smart was performed in a pediatric population, while ours
involved adult individuals. The differences in outcomes of
both studies may be associated with various physiological
reactions to protein load in the examined age groups. Fur-
thermore, there may be discrepancies in the proportion of
basal versus prandial insulin doses depending on the age of
patients, which could affect study outcomes. Moreover, the
effect of protein when mixed with carbohydrates might be
different compared to the effect of protein alone. Finally, the
impact of protein may be dose-dependent, because, in the
earlier study, 40 g of protein per meal was used, while the
protein dose in our study was much lower.
It is also important to underline that factors other than
meal size or composition may influence the rate of food
absorption and postprandial glucose patterns.The list of such
factors includes the method of preparation (e.g., cooking,
frying, or grilling), rapidity of consumption, accompanying
beverages, time elapsed since the previous meal (second-
meal phenomenon), and variability in individual rates of
gut absorption, as well as some other factors [15]. Moreover,
various types of protein consumed as a meal component or
during the load test might have affected the postmeal/load
glucose patterns [16]. All these factors could have been
responsible for the differences between the studies.
The outcomes of our study may have practical clinical
consequences as there are some small protein-based snacks
available, such as protein bars or shakes, which are small meal
options for T1DMpatients. So, it is important to provide them
with information about their impact on glucose level. This is
particularly important as, through their satiating effect, they
may be helpful in weight management [17]. An important
advantage of our study was the carefully optimized rate of
basal insulin infusion based on the earlier fasting phase of
the experiment. Consequently, we were able to exclude the
potential bias related to an excess or deficit of basal insulin
on postload glucose patterns.
A shortcoming of this report is the small number of
examined T1DM individuals. Thus, an independent confir-
mation based on a larger population is required. Additionally,
our subjects were highly preselected; they were adult T1DM
patients characterized by very good compliance prior to
the study, frequent CGMS use, and willingness to follow a
challenging study protocol. Consequently, caution is required
when extrapolating to other diabetic populations. The direct
clinical implication of our study is the recommendation that
small protein-based snacksmay be consumed by adult T1DM
CSII-treated patients without insulin bolusing.Obviously, the
general guidelines concerning daily protein consumption for
patients with diabetes should be followed [2]. The results of
this study cannot be generalized to other noncarbohydrate
food components, especially fat. Additionally, we examined
glucose patterns for 6 hours; thus, it is not possible to
exclude the protein load effect on glycemia beyond this time,
for example, during subsequent meal. Finally one has to
underline, that we have used CGM systems that are still
characterized with limited accuracy and reliability [18].
5. Summary
In conclusion, the ingestion of a pure protein load does not
seem to have a clinically significant impact on glucose levels
in adult T1DM patients treated with insulin pumps. Thus,
small protein-based snacks do not require prandial insulin
bolusing.
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